Rationale and design of the EVOLVE Short DAPT Study to assess 3‐month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2018.08.004
Abstract: Background While extended dual antiplatelet therapy (DAPT) with aspirin and a platelet (P2Y12) inhibitor after percutaneous coronary intervention (PCI) reduces the risk of stent thrombosis (ST) and myocardial infarction (MI), it also increases bleeding. Newer… read more here.
Keywords: dapt; risk; evolve short; dapt study ... See more keywords